Herbert Lepor

Q: What Schools Are Affiliated With Herbert Lepor

Herbert Lepor is affiliated with the following schools: Washington University in St. Louis, Medical College of Wisconsin, Jilin University, Stanford University, Johns Hopkins University, New York University, Harvard University

Herbert Lepor's AcademicInfluence.com Rankings

Herbert Lepor

Engineering

#2637

World Rank

#3595

Historical Rank

Biomedical Engineering

#78

World Rank

#79

Historical Rank

engineering Degrees

Herbert Lepor

Philosophy

#3934

World Rank

#6271

Historical Rank

Logic

#1515

World Rank

#2287

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Herbert Lepor's Degrees

PhD Biomedical Engineering Stanford University

Why Is Herbert Lepor Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Herbert Lepor's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. (2003) (1790)
Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations (1983) (1000)
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. (1996) (732)
Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? (1995) (461)
Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis. (1985) (407)
Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. (1998) (403)
Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. (1998) (403)
A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. (2014) (370)
The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. (1994) (340)
Proximal location of mouse prostate epithelial stem cells (2002) (322)
Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. (1993) (292)
Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. (2001) (290)
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. (1992) (287)
Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. (2004) (280)
The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. (1992) (275)
Androgen deprivation therapy in the treatment of advanced prostate cancer. (2007) (272)
E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells (2018) (239)
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. (2017) (232)
The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: a prospective assessment using validated self-administered outcome instruments. (2004) (196)
The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. (1990) (187)
Review ArticleIdiopathic Retroperitoneal Fibrosis (1979) (185)
Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. (2016) (182)
A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. (1995) (177)
Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial (1998) (175)
The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle (1992) (169)
Effects of nitric oxide on human and canine prostates. (1995) (163)
Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. (2014) (159)
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia* (1995) (151)
Open Versus Laparoscopic Versus Robot-Assisted Laparoscopic Prostatectomy: The European and US Experience. (2010) (146)
Influence of body weight and prostate volume on intraoperative, perioperative, and postoperative outcomes after radical retropubic prostatectomy. (2003) (145)
Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. (1984) (145)
Nonoperative management of benign prostatic hyperplasia. (1989) (144)
Anastomotic strictures following radical prostatectomy: insights into incidence, effectiveness of intervention, effect on continence, and factors predisposing to occurrence. (2001) (144)
The influence of hormonal therapy on survival of men with advanced prostatic cancer. (1982) (140)
Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. (2003) (140)
Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. (2002) (138)
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. (2003) (137)
The inheritance of the exstrophy-epispadias complex. (1984) (135)
The role of radical prostatectomy in the management of prostatic cancer (1987) (127)
Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. (2001) (125)
Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice (2019) (125)
Characterization and localization of nitric oxide synthase in the human prostate. (1995) (121)
Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. (1997) (121)
Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. (1993) (119)
Early removal of urinary catheter after radical retropubic prostatectomy is both feasible and desirable. (2001) (119)
Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12‐core biopsy results (2016) (118)
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. (2007) (117)
Continence following radical retropubic prostatectomy using self-reporting instruments. (2004) (116)
The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. (1998) (116)
The alpha‐adrenoceptor subtype mediating the tension of human prostatic smooth muscle (1993) (111)
Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia. (2016) (108)
The effect of obstruction on the developing bladder. (1992) (108)
Quantitative morphometry of the adult human bladder. (1992) (106)
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. (1988) (104)
Bladder wall abnormalities in myelodysplastic bladders: a computer assisted morphometric analysis. (1991) (103)
SSI Prize Essay for Male Erectile Dysfunction—Clinical ‘Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP)’ (1999) (102)
Skin preparation for the prevention of surgical site infection: which agent is best? (2009) (102)
Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. (2015) (99)
Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. (1997) (99)
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. (2007) (97)
Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? (2001) (96)
Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. (2010) (96)
Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. (1999) (93)
Autonomic receptors in human prostate adenomas. (1990) (92)
Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. (2009) (91)
Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. (2009) (90)
Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons. (2001) (88)
Pathophysiology of lower urinary tract symptoms in the aging male population. (2005) (88)
&agr;-Blockers for benign prostatic hyperplasia: the new era (2012) (87)
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. (2002) (87)
How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. (2016) (86)
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. (2015) (86)
Role of alpha‐adrenergic blockers in the treatment of benign prostatic hyperplasia (1990) (85)
Contemporary evaluation of operative parameters and complications related to open radical retropubic prostatectomy. (2003) (84)
Quantifying the Smooth Muscle Content of the Prostate Using Double Immunoenzymatic Staining and Color-Assisted Image Analysis (1992) (84)
Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. (1993) (84)
Alpha 1 adrenoceptor subtypes in the human prostate. (1993) (84)
Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. (2005) (83)
An artificial somatic-autonomic reflex pathway procedure for bladder control in children with spina bifida. (2005) (83)
Proximal Prostatic Stem Cells Are Programmed to Regenerate a Proximal‐Distal Ductal Axis (2006) (82)
Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. (2007) (82)
Primary bladder closure and bladder neck reconstruction in classical bladder exstrophy. (1983) (82)
Analysis of apical soft tissue margins during radical retropubic prostatectomy. (2001) (81)
Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis (2018) (81)
Pathophysiology of clinical benign prostatic hyperplasia. (1995) (81)
Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. (2004) (81)
Randomized double-blind study comparing the effectiveness of balloon dilation of the prostate and cystoscopy for the treatment of symptomatic benign prostatic hyperplasia. (1992) (80)
Relationship between prostatc epithelial volume and serum prostate-specific antigen levels (1994) (79)
Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer. (2015) (78)
Localization of endothelin receptors in the human prostate. (1994) (78)
Removal of urinary catheter on postoperative day 3 or 4 after radical retropubic prostatectomy. (2003) (77)
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. (2009) (77)
Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. (2015) (77)
Contractile properties of human prostate adenomas and the development of infravesical obstruction (1989) (76)
A comparison of the urological complications associated with long-term management of quadriplegics with and without chronic indwelling urinary catheters. (1992) (75)
The pathophysiology of lower urinary tract symptoms in the ageing male population. (1998) (73)
Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. (2009) (72)
Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. (1992) (71)
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. (2008) (71)
The Institutional Learning Curve of Magnetic Resonance Imaging‐Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years (2018) (70)
Radical retropubic prostatectomy reduces symptom scores and improves quality of life in men with moderate and severe lower urinary tract symptoms. (1999) (70)
Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study. (2014) (70)
Anti‐desmin vs. anti‐actin for quantifying the area density of prostate smooth muscle (1992) (69)
Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. (1999) (68)
Pathophysiology of benign prostatic hyperplasia in the aging male population. (2005) (67)
Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. (2011) (66)
Site of positive surgical margins influences biochemical recurrence after radical prostatectomy (2009) (66)
Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. (2014) (65)
Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH (2010) (65)
A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. (1990) (65)
Binding and functional properties of endothelin receptor subtypes in the human prostate. (1994) (63)
Characterization and localization of the muscarinic cholinergic receptor in human prostatic tissue. (1984) (62)
Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. (2013) (62)
Alpha 2 adrenergic receptors in hyperplastic human prostate: identification and characterization using [3H] rauwolscine. (1986) (60)
Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer. (2014) (60)
Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. (1989) (59)
Total prostate and transition zone volumes, and transition zone index are poorly correlated with objective measures of clinical benign prostatic hyperplasia. (1997) (59)
Medical therapy for benign prostatic hyperplasia. (1993) (59)
Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015 (2018) (58)
Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer (2012) (57)
Post-prostatectomy incontinence during sexual activity: a single center prevalence study. (2011) (57)
Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia (2012) (57)
Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. (1998) (56)
Endothelin‐1 production and agonist activities in cultured prostate‐derived cells: Implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia (1998) (56)
Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen. (1999) (56)
The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. (2000) (55)
Prostatic alpha 1-adrenoceptors and uroselectivity. (1997) (55)
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. (2011) (54)
Alpha blockade for the treatment of benign prostatic hyperplasia. (1995) (54)
Role of intraoperative biopsies during radical retropubic prostatectomy. (2004) (53)
Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. (1998) (53)
Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359 (1999) (52)
The New York University nerve sparing algorithm decreases the rate of positive surgical margins following radical retropubic prostatectomy. (2003) (52)
LHRH Agonists for the Treatment of Prostate Cancer: 2012. (2012) (51)
Localization of the alpha 1A-adrenoceptor in the human prostate. (1995) (51)
The prostatic utricle is not a Müllerian duct remnant: immunohistochemical evidence for a distinct urogenital sinus origin. (2004) (51)
Can contemporary transrectal prostate biopsy accurately select candidates for hemi‐ablative focal therapy of prostate cancer? (2009) (51)
Factors predisposing to the development of anastomotic strictures in a single‐surgeon series of radical retropubic prostatectomies (2006) (49)
Cigarette side-stream smoke lung and bladder carcinogenesis: inducing mutagenic acrolein-DNA adducts, inhibiting DNA repair and enhancing anchorage-independent-growth cell transformation (2015) (49)
The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. (2017) (49)
Does a nerve‐sparing technique or potency affect continence after open radical retropubic prostatectomy? (2008) (49)
A review of surgical techniques for radical prostatectomy. (2005) (49)
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. (1992) (48)
Anatomic considerations of the penis and its lymphatic drainage. (1992) (47)
Characterization of muscarinic cholinergic receptor binding in the vas deferens, bladder, prostate and penis of the rabbit. (1984) (46)
Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells (2014) (46)
Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate‐specific antigen (2015) (46)
Outcomes for men younger than 50 years undergoing radical prostatectomy. (2005) (46)
Transrectal ultrasonography in the diagnosis and staging of carcinoma of the prostate. (1988) (45)
Isolation of mouse THP gene promoter and demonstration of its kidney-specific activity in transgenic mice. (2002) (45)
The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. (2006) (45)
Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. (1990) (44)
Filling and voiding symptoms in the American Urological Association symptom index: the value of their distinction in a Veterans Affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia. (2000) (43)
Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. (1995) (43)
The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. (1992) (43)
A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. (1994) (43)
Inguinal hernias in men undergoing open radical retropubic prostatectomy. (2007) (43)
Smooth muscle development in the obstructed fetal bladder. (1997) (43)
The efficacy and safety of terazosin for the treatment of symptomatic BPH (1991) (42)
Status of radical prostatectomy in 2009: is there medical evidence to justify the robotic approach? (2009) (42)
The role of bladder neck biopsy in men undergoing radical retropubic prostatectomy with preservation of the bladder neck. (1998) (41)
Morphometric analysis of pediatric and nonhyperplastic prostate glands: Evidence that BPH is not a unique stromal process (1997) (40)
Gene polymorphisms and prostate cancer: the evidence (2009) (40)
Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer. (2013) (40)
Alpha 1 adrenergic receptors in canine lower genitourinary tissues: insight into development and function. (1987) (39)
Vascular targeted photodynamic therapy for localized prostate cancer. (2008) (39)
Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. (2011) (39)
Long-term results of radical prostatectomy in clinically localized prostate cancer: experience at the Johns Hopkins Hospital. (1988) (39)
Spontaneous retroperitoneal hemorrhage caused by segmental arterial mediolysis. (2006) (39)
Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. (1994) (39)
Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? (2009) (38)
Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. (2017) (38)
RADICAL RETROPUBLIC PROSTATECTOMY (2001) (38)
Altered smooth muscle development and innervation in the lower genitourinary and gastrointestinal tract of the male human fetus with myelomeningocele. (1998) (37)
The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia. (1991) (36)
Time to return to work and physical activity following open radical retropubic prostatectomy. (2006) (36)
Generation of active TGF‐β by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines (2000) (36)
Patient centered outcomes in prostate cancer treatment: predictors of satisfaction up to 2 years after open radical retropubic prostatectomy. (2010) (36)
The role of preoperative epoetin alfa in men undergoing radical retropubic prostatectomy. (2000) (36)
Muscarinic cholinergic receptors in bladder exstrophy: insights into surgical management. (1985) (35)
Comparison of single-agent androgen suppression for advanced prostate cancer. (2005) (35)
The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain. (1988) (35)
Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy. (2013) (35)
Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. (2012) (35)
Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. (1997) (34)
Benign prostatic hyperplasia. (1995) (34)
The effect of surgical intervention for stress urinary incontinence (UI) on post‐prostatectomy UI during sexual activity (2012) (33)
Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. (2017) (33)
Prostate cancer: radical prostatectomy. (2003) (32)
Open versus laparoscopic radical prostatectomy. (2005) (32)
Down regulation of the muscarinic cholinergic receptor of the rat prostate following castration. (1985) (31)
Disseminated intravascular coagulation in prostatic carcinoma reversed by ketoconazole. (1987) (31)
Alpha 2 adrenergic receptors in canine prostate: biochemical and functional correlations. (1987) (31)
Determination of norepinephrine levels in the adult human prostate. (1990) (31)
Radical prostatectomy improves and prevents age dependent progression of lower urinary tract symptoms. (2014) (30)
Idiopathic retroperitoneal fibrosis. (1979) (30)
Nitric oxide synthase in dog urethra: a histochemical and pharmacological analysis (1995) (30)
Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. (2009) (30)
Qualitative study on decision‐making by prostate cancer physicians during active surveillance (2017) (29)
Likert score 3 prostate lesions: Association between whole‐lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy (2016) (29)
Binding and functional properties of alpha1 adrenoceptors in different regions of the human prostate. (1993) (29)
Urethral reconstruction in boys with classical bladder exstrophy. (1984) (28)
The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH (1992) (28)
Complex Mechanisms in Prostatic Inflammatory Response (2009) (28)
Tamsulosin reduces the incidence of acute urinary retention following early removal of the urinary catheter after radical retropubic prostatectomy. (2003) (28)
MP67-14 PREDICTIVE VALUE OF NEGATIVE 3T MULTIPARAMETRIC PROSTATE MRI ON 12 CORE BIOPSY RESULTS (2014) (28)
Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian-American men. (1996) (27)
Localization of P2Y1 purinoceptor transcripts in the rat penis and urinary bladder. (1998) (27)
Bmp7 Functions via a Polarity Mechanism to Promote Cloacal Septation (2012) (27)
Transforming growth factor‐β is an autocrine mitogen for a novel androgen‐responsive murine prostatic smooth muscle cell line, PSMC1 (2000) (27)
Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. (2008) (27)
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. (2015) (27)
The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. (2007) (26)
Effects of the Selective α1A‐Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double‐Blind, Placebo‐ and Moxifloxacin‐Controlled Study (2010) (26)
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. (2017) (26)
Binding and functional properties of alpha 1 adrenoceptors and area density of smooth muscle in the canine prostate. (1992) (26)
Identification of genes associated with stromal hyperplasia and glandular atrophy of the prostate by mRNA differential display. (1998) (25)
Laterality alone should not drive selection of candidates for hemi-ablative focal therapy. (2009) (25)
Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (2001) (25)
Gleason 6 prostate cancer: serious malignancy or toothless lion? (2014) (25)
Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex Doppler findings in 174 men after RRP (2002) (25)
Silodosin for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular Tolerability (2010) (25)
Medical Treatment of Benign Prostatic Hyperplasia (1988) (25)
Muscarinic cholinergic receptors in normal pediatric and myelodysplastic bladders. (1989) (25)
Comparison of alpha1 Adrenoceptors in the Prostate Capsule of Men with Symptomatic and Asymptomatic Benign Prostatic Hyperplasia (1991) (24)
LEF1 identifies androgen-independent epithelium in the developing prostate. (2011) (24)
Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer. (2018) (24)
Testosterone in prostate cancer: the Bethesda consensus (2012) (24)
Histopathologic and clinical features of vesical diverticula. (2013) (23)
Selecting candidates for radical prostatectomy. (2000) (23)
Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein. (2001) (23)
A continence index predicts the early return of urinary continence after radical retropubic prostatectomy. (2000) (23)
Practical considerations in radical retropubic prostatectomy. (2003) (23)
Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. (2011) (23)
Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer. (2018) (23)
Evaluating men with benign prostatic hyperplasia. (2004) (23)
Postoperative blood loss predicts the development of urinary extravasation on cystogram following radical retropubic prostatectomy. (2006) (23)
The pathophysiology of clinical BPH. (1994) (22)
A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. (1996) (22)
Therapeutic controversies: clinical treatment of benign prostatic hyperplasia. (1995) (22)
Managing and preventing acute urinary retention. (2005) (22)
Radical Retropubic and Perineal Prostatectomy (2012) (21)
Muscarinic cholinergic receptors in the normal and neurogenic human bladder. (1989) (21)
Blood loss during radical prostatectomy: impact on clinical, oncological and functional outcomes and complication rates (2012) (21)
Spontaneous renal artery dissection. (2007) (21)
The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. (2006) (21)
Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. (2012) (21)
Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy. (2016) (21)
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. (2002) (21)
Detection of prostate cancer in males with prostatism (1994) (21)
Radical retropubic prostatectomy. Preoperative management. (2001) (21)
Identification of a dihydropyridine as a potent alpha1a adrenoceptor-selective antagonist that inhibits phenylephrine-induced contraction of the human prostate. (1998) (21)
The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate (1996) (21)
Evaluation of the effect of endothelin-1 and characterization of the selective endothelin a receptor antagonist PD155080 in the prostate. (1997) (20)
Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. (2005) (20)
α1-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms (2000) (20)
Adoption of an integrated radiology reading room within a urologic oncology clinic: initial experience in facilitating clinician consultations. (2014) (20)
Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies (2017) (19)
Identification and characterization of alpha 1 adrenergic receptors in the canine prostate using [125I]-Heat. (1987) (19)
The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. (1989) (19)
Prostate adenocarcinoma presenting as a large supraclavicular mass. (2001) (19)
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. (1995) (19)
Long-term satisfaction and predictors of use of intracorporeal injections for post-prostatectomy erectile dysfunction. (2013) (19)
Benign prostatic hyperplasia: current clinical practice. (2010) (19)
Intraoperative frozen section analysis of urethral margin biopsies during radical prostatectomy. (2011) (18)
Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy. (2008) (18)
Endothelins in canine genitourinary tissues. (1997) (18)
Clinical evaluation of a novel method for the measurement of prostate‐specific antigen, AccuPSATM, as a predictor of 5‐year biochemical recurrence‐free survival after radical prostatectomy: results of a pilot study (2012) (18)
The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer. (2018) (18)
Benign prostatic hyperplasia: Preface (1990) (18)
NOCTURNAL PENILE TUMESCENCE ACTIVITY IN 81 PATIENTS PRESENTING WITH ERECTILE DYSFUNCTION (ED) AFTER NERVE SPARING RADICAL PROSTATECTOMY (NSRRP) (1999) (17)
Innovative surgical management of idiopathic retroperitoneal fibrosis. (1989) (17)
Multi-parametric MRI imaging of the prostate—implications for focal therapy (2017) (17)
Reoperation versus observation in men with major bleeding after radical retropubic prostatectomy. (2005) (17)
Identifying quantitative in vivo multi-parametric MRI features for treatment related changes after laser interstitial thermal therapy of prostate cancer (2014) (16)
The stereospecificity of LY253352 for α1‐adrenoceptor binding sites in the brain and prostate (1988) (16)
Mitogenic activation of human prostate‐derived fibromuscular stromal cells by bradykinin (1999) (16)
Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease. (2009) (15)
Prostate-specific antigen testing and prostate cancer screening. (2010) (15)
Optimizing the detection of subclinical inguinal hernias in men undergoing open radical retropubic prostatectomy (2010) (15)
Practical Barriers to Obtaining Pre-Biopsy Prostate MRI: Assessment in Over 1,500 Consecutive Men Undergoing Prostate Biopsy in a Single Urologic Practice (2016) (15)
Radical Prostatectomy: Status and Opportunities for Improving Outcomes (2004) (15)
This month in investigative urology: alpha adrenergic innervation of the prostate: insights into pharmacotherapy of BPH. (1990) (14)
Comparison of health‐related quality‐of‐life outcomes for African‐American and Caucasian‐American men after radical prostatectomy (2012) (14)
Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. (2011) (14)
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. (2019) (14)
alpha(1)-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. (2000) (14)
Report of a unique meeting between the alpha-blocker subcommittee and the pharmaceutical industry. (1996) (13)
Multiparametric magnetic resonance imaging identifies significant apical prostate cancers (2018) (13)
Neurovascular bundle resection: does it improve the margins? (2010) (13)
Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System. (2020) (13)
Concordance and Performance of 4Kscore® and SelectMDx® for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. (2020) (13)
Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. (2010) (13)
RETROGRADE EJACULATION INDUCED BY SILODOSIN IS THE RESULT OF RELAXATION OF SMOOTH MUSCULATURE IN THE MALE URO-GENITAL TRACTS AND IS ASSOCIATED WITH GREATER URODYNAMIC AND SYMPTOMATIC IMPROVEMENTS IN MEN LUTS SECONDARY TO BPH (2009) (13)
Open versus robotic radical prostatectomy. (2006) (13)
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? (2002) (13)
Predicting continence following radical prostatectomy (2001) (13)
Informational needs during active surveillance for prostate cancer: A qualitative study. (2017) (12)
The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia. (2008) (12)
Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy (2009) (12)
Muscarinic cholinergic and alpha 2-adrenergic receptors in the epithelium and muscularis of the human ileum. (1990) (12)
A prospective comparative analysis of the accuracy of HistoScanning and multiparametric magnetic resonance imaging in the localization of prostate cancer among men undergoing radical prostatectomy. (2016) (11)
Application of the PRECISION Trial Biopsy Strategy to a Contemporary MRI-Targeted Biopsy Cohort: How Many Clinically Significant Prostate Cancers are Missed? (2020) (11)
Diagnostic Strategies for Prostate Cancer (2011) (11)
Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone (2020) (11)
Uroplakins play conserved roles in egg fertilization and acquired additional urothelial functions during mammalian divergence (2018) (11)
10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era. (2015) (11)
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. (2003) (11)
Oncologic, Functional, and Cost Analysis of Open, Laparoscopic, and Robotic Radical Prostatectomy (2010) (11)
Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing post‐prostatectomy hernia (2012) (10)
Decreased prostatic secretory function in canine benign prostatic hyperplasia is not due to decreased levels of muscarinic cholinergic receptors. (1984) (10)
Management of localized prostate cancer and an incidental ureteral duplication with upper pole ectopic ureter inserting into the prostatic urethra. (2008) (10)
Management of clinically localized prostate cancer. (2004) (10)
Comparison of alpha 1 adrenoceptors in the prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. (1991) (10)
The treatment of benign prostatic hyperplasia with alpha1 blockers (1994) (10)
Binding and functional properties of doxazosin in the human prostate adenoma and canine brain (1990) (10)
Teaching Hospitals and the Disconnect Between Technology Adoption and Comparative Effectiveness Research: The Case of the Surgical Robot (2017) (10)
Is the apical soft tissue margin a better predictor of biochemical recurrence than the surgical specimen? (2011) (10)
Durability and retreatment rates of minimal invasive treatments of benign prostatic hyperplasia: a cross-analysis of the literature. (2010) (10)
Editorial: Benign Prostatic Hyperplasia (1995) (10)
Prostatic alpha adrenoceptors. (1994) (9)
The effect of electrocautery on neurotransmitter receptor binding assays in the canine prostate. (1988) (9)
Panel IX: Alternatives to surgery for benign prostatic hyperplasia (1992) (9)
Volume-specific cutoffs are necessary for reproducible application of prostate-specific antigen density of the transition zone in prostate cancer detection. (2001) (9)
Comparison of muscarinic cholinergic and alpha adrenergic receptors in canine ileum, colon, intestinal urinary reservoirs and bladder. (1989) (9)
Heterogeneity in active surveillance protocols worldwide. (2014) (9)
1132: Creation of a Somatic-Autonomic Reflex Pathway for Treatment of Neurogenic Bladder in Patients with Spinal Cord Injury: Preliminary Results of First 2 USA Patients (2005) (9)
Perianastomotic injection of autologous fat at the time of radical retropubic prostatectomy. (1994) (8)
Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. (2013) (8)
Functional Domains of Androgen Receptor Coactivator p44/Mep50/WDR77and Its Interaction with Smad1 (2013) (8)
Alpha adrenergic antagonists for the treatment of symptomatic BPH. (1989) (8)
Alpha blockers for the treatment of benign prostatic hyperplasia. (2007) (8)
Para‐anastomotic haematoma volume predicts the presence of anastomotic extravasation after radical retropubic prostatectomy (2010) (8)
The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (2010) (8)
Transabdominal sonocystography: a novel technique to assess vesicourethral extravasation following radical prostatectomy. (2008) (8)
Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition (2016) (8)
Quantitative evaluation of treatment related changes on multi-parametric MRI after laser interstitial thermal therapy of prostate cancer (2013) (8)
Landmark studies impacting the medical management of benign prostatic hyperplasia. (2003) (8)
α1‐Adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain (1992) (7)
New use for alpha blockers: benign prostatic hyperplasia. (1994) (7)
Renewing intimacy: advances in treating erectile dysfunction postprostatectomy. (2008) (7)
The Association of Veterans' PSA Screening Rates with Changes in USPSTF Recommendations. (2020) (7)
Long‐Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15‐Year Longitudinal Study (2018) (7)
Alpha1−adrenergic blockers in the medical management of benign prostatic hyperplasia (1992) (7)
In Reply: Re: Editorial: Benign Prostatic Hyperplasia (1996) (7)
Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy. (2015) (7)
PKM2 is essential for bladder cancer growth and maintenance. (2021) (7)
Stromal/epithelial interactions of murine prostatic cell lines in vivo: A model for benign prostatic hyperplasia and the effect of doxazosin on tissue size (2003) (6)
Radical retropubic prostatectomy. (2001) (6)
Copolymerization of single-cell nucleic acids into balls of acrylamide gel (2019) (6)
Indications and Trends in Pelvic Lymph Node Dissection for Prostate Cancer (2011) (6)
Focal Ablation of Prostate Cancer. (2018) (6)
Optimizing the Role of Hormonal Therapy in the Management of Prostate Cancer (2005) (6)
T1 hyperintensity of bladder urine at prostate MRI: frequency and comparison with urinalysis findings. (2011) (6)
5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer. (2021) (6)
Prostate Selectivity of Alpha-Blockers: From Receptor Biology to Clinical Medicine (1996) (6)
Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial - risk factors and concomitance with hypertension (1998) (5)
The treatment of benign prostatic hyperplasia: a glimpse into the future. (1995) (5)
MP53-11 A PRE-BIOPSY NOMOGRAM FOR PREDICTION OF THE RISK OF GLEASON SCORE = 7 PROSTATE CANCER ON COMBINED MRI-US FUSION TARGETED AND SYSTEMATIC PROSTATE BIOPSY AMONG MEN WITH NO PREVIOUS BIOPSY (2016) (5)
Oncological control following partial gland ablation for intermediate-risk prostate cancer. (2020) (5)
Alpha-Blockade for Benign Prostatic Hyperplasia (1991) (5)
Testosterone Deficiency and the Prostate. (2016) (5)
Selecting treatment for high-risk, localized prostate cancer: the case for radical prostatectomy. (2002) (4)
MP48-03 TESTOSTERONE REPLACEMENT THERAPY IN PATIENTS WITH PROSTATE CANCER AFTER PROSTATECTOMY: A 5-YEAR SINGLE CENTER EXPERIENCE (2014) (4)
1640: Development of a Nomogram to Predict Acute Urinary Retention or BPH-Related Surgery with or without Medical Therapy in Men with BPH Based on Data from the MTOPS Trial (2005) (4)
Health state utilities among contemporary prostate cancer patients on active surveillance (2018) (4)
Alpha blockade in the therapy of benign prostatic hyperplasia (1993) (4)
Outcomes of extremely low risk prostate cancer following radical prostatectomy (2011) (4)
The role of radical prostatectomy in the treatment of cancer of the prostate. (1989) (4)
IS THE APICAL SOFT TISSUE MARGIN (ASTM) A BETTER PREDICTOR OF BIOCHEMICAL RECURRENCE (BR) THAN THE SURGICAL SPECIMEN MARGIN (2008) (4)
Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration (2021) (4)
The binding and functional properties of voltage dependent calcium channel receptors in pediatric normal and myelodysplastic bladders. (1991) (4)
Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients. (2019) (4)
The short‐term use of erythropoetin‐stimulating agents: impact on the biochemical recurrence of prostate cancer (2011) (4)
Alternatives to surgery for benign prostatic hyperplasia. (1992) (4)
Optimizing patient selection for focal therapy—mapping and ablating the index lesion (2018) (4)
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. (2012) (4)
Does open radical retropubic prostatectomy decrease the risk of acute urinary retention? (2008) (4)
Magnetic resonance imaging in prostate cancer (2017) (3)
Surgical Treatment of Prostate Carcinoma. (2017) (3)
A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group. (1992) (3)
Transperineal Sonocystography (2010) (3)
Expression of the ETA and ETB Endothelin Receptor Subtype mRNA in Human Detrusor Cultured Smooth Muscle Cells (2000) (3)
Long-term Satisfaction After Open Radical Prostatectomy. (2015) (3)
685: Factors Predisposing to the Development of Post-Radical Prostatectomy Anastamotic Strictures in a Single-Surgeon Series (2005) (3)
Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy (2017) (3)
Combination medical therapy for benign prostatic hyperplasia. (1995) (3)
Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society. (2021) (3)
PD34-02 OUTCOMES OF MRI-US FUSION TARGETED BIOPSY IN THE RISK STRATIFICATION OF ACTIVE SURVEILLANCE CANDIDATES (2015) (3)
Long-term assessment of the safety and efficacy of terazosin in a single urologic practice (1994) (3)
MEN WITH UNILATERAL PROSTATE CANCER HAVE MORE FAVORABLE PATHOLOGIC AND ONCOLOGIC OUTCOMES THAN THOSE WITH BILATERAL DISEASE: IMPLICATIONS FOR FOCAL THERAPY (2008) (3)
Muscarinic Cholinergic Receptors in Bladder Exstrophy (1999) (3)
Characterization of 1,4, dihydropyridine calcium channel binding sites in the human prostate. (1990) (3)
Predicting cancer on repeat biopsy: Results of a multicenter prospective evaluation of complexed PSA (2003) (3)
Smooth muscle content and neuro-endocrine physiology of human benign prostatic hyperplasia (1992) (2)
DO BIOPSY CHARACTERISTICS PREDICT UNILATERAL PROSTATE CANCER ON RADICAL PROSTATECTOMY (2008) (2)
Combination therapy for non-neurogenic male lower urinary tract symptoms: 1 + 1 does not equal 2. (2013) (2)
Early functional outcomes following partial gland cryo-ablation. (2022) (2)
Controversies old and new (1995) (2)
Laser treatment of benign prostatic hyperplasia (BPH) workshop. (1994) (2)
Insights into the natural history and treatment of benign prostatic hyperplasia. (2006) (2)
Is Targeted Therapy of Prostate Cancer Ready for Prime Time? (2016) (2)
MP77-14 OUTCOMES OF MRI-US FUSION TARGETED PROSTATE BIOPSY IN MEN WITHOUT HISTORY OF PREVIOUS BIOPSY: REDUCTION OF OVER-DETECTION AND IMPROVED RISK STRATIFICATION. (2015) (2)
80 RADICAL PROSTATECTOMY (RP) PREVENTS AGE-DEPENDENT PROGRESSION OF LOWER URINARY TRACT SYMPTOMS (LUTS) (2013) (2)
Is Early or Delayed Androgen Deprivation Best (1987) (2)
The alpha-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. (1996) (2)
BPH: Predicting TWOC failure in acute urinary retention (2012) (2)
Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. (2016) (2)
Expression of the ET(A) and ET(B) endothelin receptor subtype mRNA in human detrusor cultured smooth muscle cells. (2000) (2)
Penile Rehabilitation Postprostatectomy: Is There a Role for MUSE? (2008) (2)
Focal Ablation of Prostate Cancer. (2018) (2)
The role of radical prostatectomy in the management of stage B adenocarcinoma of the prostate. (1987) (2)
Challenges in the Detection and Diagnosis of Bladder Dysfunction: Optimal Strategies for the Primary Care Physician (2004) (2)
Using the 4Kscore Test and Magnetic Resonance Imaging Results to Avoid Unnecessary Prostate Biopsy. (2015) (2)
Challenging the Current Treatment Paradigm of Androgen-Independent Prostate Cancer (2007) (2)
Treatment of benign prostatic hyperplasia (1996) (2)
Novel role of X-linked inhibitor of apoptosis protein (XIAP) in bladder cancer cell invasion and prediction of disease progression. (2014) (2)
Pharmacological evidence of nitric oxide synthase activity in human and canine prostate (1994) (1)
Lap pak for abdominal retraction. (2012) (1)
Prostate Cancer Academy 2016: Presentation summaries. (2016) (1)
Advances in genitourinary surgery: highlights from the 114th meeting of the american association of genitourinary surgeons april 5-8, 2000, san antonio, tex. (2000) (1)
A RANDOMIZED PROSPECTIVE PENILE REHABILITATION STUDY OF THE USE OF NIGHTLY INTRAURETHRAL ALPROSTADIL (IUA) VS SILDENAFIL CITRATE (SC) AFTER NERVE SPARING PROSTATECTOMY (2009) (1)
MP23-05 DEVELOPMENT OF NOVEL KNOCK-IN MICE PROVIDES DIRECT EVIDENCE THAT UROPLAKIN IA IS THE UROTHELIAL RECEPTOR FOR TYPE 1-PILIATED UROPATHOGENIC E. COLI (UPEC) (2018) (1)
Primary aldosteronism caused by unilateral adrenal hyperplasia. (2000) (1)
Book ReviewProstatic Disorders (1989) (1)
Minimally invasive ablative therapies for the treatment of prostate cancer. (2011) (1)
Investigational agents for benign prostatic hyperplasia (2010) (1)
DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY TO DEFINE ELECTROCARDIOGRAPHIC EFFECTS OF SILODOSIN, A UROSELECTIVE α-ADRENERGIC ANTAGONIST (2008) (1)
MP77-18 OUTCOMES OF MRI-US FUSION TARGETED PROSTATE BIOPSY IN MEN WITH HISTORY OF PROSTATIC INTRAEPITHELIAL NEOPLASIA AND/OR ATYPICAL SMALL ACINAR PROLIFERATION: EVIDENCE FOR AN ALTERATION OF CURRENT PRACTICE. (2015) (1)
Prevention and management of complications associated with open radical retropubic prostatectomy (2008) (1)
Alpha 1-adrenoceptor selectivity: clinical or theoretical benefit? (1995) (1)
A PROSPECTIVE CONCURRENT STUDY OF THE LONGITUDINAL EFFECTS ON STRETCHED PENILE LENGTH AFTER ROBOTIC AND OPEN PROSTATECTOMY FROM AN INTRAURETHRAL ALPROSTADIL VS SILDENAFIL PENILE REHABILITATION STUDY (2009) (1)
MP46-01 DEFICIENCY OF HOST MICROBIOME BY ANTIBIOTIC EXPOSURE COMPROMISES INNATE IMMUNE RESPONSES OF THE URINARY BLADDER AGAINST UROPATHOGENIC E. COLI (2020) (1)
Historical Overview of Medical Therapy for Benign Prostatic Hyperplasia (2005) (1)
Robotically speaking (2011) (1)
BMP7 INHIBITS NOTCH1 ACTIVITY AND AFFECTS DISTRIBUTION OF NOTCH1-POSITIVE PROGENITOR CELLS IN THE PROSTATE GLAND (2008) (1)
Advances in Alpha-Blocker Therapy in the Management of Urological Disorders (2006) (1)
1433 EFFECTS OF SILODOSIN IN MEN WITH MODERATE OR SEVERE CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: A DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY (2011) (1)
416 USING SOCIAL MEDIA TO GAUGE REACTION TO THE UNITED STATES PREVENTIVE SERVICES TASK FORCE'S (USPSTF) REPORT TWITTER AS AN INVESTIGATIVE TOOL (2012) (1)
The effect of local compression and topical epinephrine on perioperative bleeding and degree of urinary extravasation on postoperative cystogram following radical retropubic prostatectomy. (2010) (1)
Cause-Specific Actuarial Survival Analysis? the Optimal Method for Reporting Survival Data in Men with Carcinoma of the Prostate (CaP) (1987) (1)
DOES THE LOCATION OR EXTENT OF POSITIVE SURGICAL MARGINS (PSM) IMPACT BIOCHEMICAL RECURRENCE (BR) FOLLOWING OPEN RADICAL RETROPUBIC PROSTATECTOMY (ORRP) (2008) (1)
PD4-11 THE RELATIONSHIP OF INCREASING MRI SUSPICION SCORE AND THE IDENTIFICATION OF HIGH GRADE PROSTATE CANCER ON MRI FUSION TARGETED BIOPSY. (2015) (1)
Redefining Prostate Cancer: An Innovative Guide to Diagnosis and Treatment (2013) (1)
The stereospecificity of LY253352 for alpha 1-adrenoceptor binding sites in the brain and prostate. (1988) (1)
E‐CIGARETTE SMOKE IS POTENTIALLY BLADDER CARCINOGENIC – IT INDUCES TUMORIGENIC DNA ADDUCTS AND INHIBITS DNA REPAIR IN UROTHELIAL CELLS.: PNFBA‐11 (2017) (1)
Phase I Study of Bi-weekly Paclitaxel and Definitive Radiation in Androgen Ablated Locally Advanced Prostate Cancer (2007) (1)
1133 P27KIP1 DOWN-REGULATES EGFR EXPRESSION VIA INHIBITION OF JNK/C-JUN TRANSACTIVATION: A NOVEL FUNCTION OF P27KIP1 IN TUMOR SUPPRESSION DEFICIENT IN METASTATIC BLADDER CANCER CELLS (2013) (1)
MP45-13 INTERMEDIATE AND LONG-TERM PREDICTORS OF SATISFACTION FOLLOWING OPEN RADICAL RETROPUBIC PROSTATECTOMY (2014) (1)
Does the medical evidence justify robotic assisted laparoscopic radical prostatectomy as the new gold standard for radical prostatectomy? (2013) (1)
Guidelines for Reporting Studies of Treatment for Prostatic Cancer (1988) (1)
1487: Are Cancers Diagnosed in Longterm Follow-Up of HGPIN Clinically Significant? (2006) (1)
914 IN VIVO ROLE OF RAB27B IN UROTHELIAL ADHESION AND INVASION BY UROPATHOGENIC E.COLI (2012) (1)
Effects of α-adrenergic agonist on neobladder water and electrolyte transport (1994) (1)
LONGITUDINAL AND PROSPECTIVE SELF ASSESSMENT OF SATISFACTION UP TO 7 YEARS AFTER OPEN RETROPUBIC RADICAL PROSTATECTOMY (2009) (1)
Surgical, Pharmacological, and Technological Advances in Adult and Pediatric Urology - State of the Art: Highlights of the 7th Annual NYU Department of Urology Postgraduate Course December 7-9, 2000, New York, NY. (2002) (1)
892: Persistent Uroplakin Expression in Advanced Urothelial Carcinomas: Implications in Clinical Outcome (2007) (1)
Partial gland cryoablation for prostate cancer — where are we? (2022) (1)
MRI predicts prostatic urethral involvement in men undergoing radical prostatectomy: implications for cryo-ablation of localized prostate cancer (2021) (1)
Radical prostatectomy for long-term functional and oncologic outcomes. (2012) (1)
TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. AUTHORS' REPLY (1996) (1)
Matrix changes in the bladder associated with normal aging. (1995) (1)
PD08-11 COMBINING MRI-US FUSION TARGETED BIOPSY WITH SYSTEMATIC BIOPSY IMPROVES RISK STRATIFICATION OF ACTIVE SURVEILLANCE CANDIDATES (2016) (1)
Title Duration of Androgen Deprivation in Locally Advanced Prostate Cancer : Long-Term (2017) (0)
Reply: To PMID 26163812. (2015) (0)
419 FACTORS ASSOCIATED WITH THE EARLY ACQUISITION OF THE SURGICAL ROBOT BY HOSPITALS IN THE UNITED STATES (2012) (0)
MP69-16 UTILITY OF INTRAOPERATIVE APICAL SOFT TISSUE MARGIN ASSESSMENT DURING OPEN RADICAL RETROPUBIC PROSTATECTOMY (2016) (0)
414: Prostatic Stem Cells: Their Location and Biological Properties (2005) (0)
A comparison of anticholinergic therapies in the treatment of overactive bladder. (2001) (0)
1128 INVASIVE BLADDER CANCER CELLS ARE DEFICIENT IN DNA REPAIR AND HAVE MUTATOR PHENOTYPES THAT ARE DUE TO SUPPRESSION OF P63 GENE EXPRESSION (2013) (0)
MP46-04 SINGLE-CELL TRANSCRIPTOMICS AND MULTIPLEX FLOW-CYTOMETRY REVEAL SIGNIFICANCE INFLUENCES OF MICROBIOTA ON IMMUNE CELL MAKEUP OF MOUSE URINARY BLADDER (2020) (0)
MP02-05 CDKN2A REGULATES OXIDATIVE STRESS AND AUTOPHAGY IN UROTHELIAL DEFENSE AGAINST URINARY TRACT INFECTION (2022) (0)
1948 THREE YEAR POSTOPERATIVE PSA FOLLOWING OPEN RADICAL RETROPUBIC PROSTATECTOMY (ORRP) IS A PREDICTOR FOR DELAYED BIOCHEMICAL RECURRENCES (BCR) (2010) (0)
Uro-oncological controversies in euro-oncology: highlights from the European association of urology section of oncological urology, january 15-17, 2010, vienna, austria. (2010) (0)
Editorial Comment. (2017) (0)
MP30-01 TWO YEAR ONCOLOGICAL OUTCOMES FOLLOWING FOCAL LASER ABLATION (2018) (0)
781 SV40 LARGE T ANTIGEN COOPERATES WITH ACTIVATED HA-RAS IN INDUCING RAPID-PROGRESSING UROTHELIAL CARCINOMAS (2010) (0)
Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile. (2023) (0)
255 MESENCHYMAL SIGNAL PROMOTES TOPOLOGICAL SEPARATION OF THE URETHRAL AND RECTAL COMPARTMENTS. INSIGHTS INTO THE HUMAN CLOACAL SYNDROMES (2011) (0)
New Directions in the Management of Advanced Prostate Cancer (2007) (0)
MP24-10 DIABETIC CONDITIONS IMPAIR NEUTROPHIL RECRUITMENT INTO THE UROTHELIUM AND MARKEDLY DELAY THE CLEARANCE OF INTRACELLULAR BACTERIAL COMMUNITY OF UROPATHOGENIC E. COLI (2016) (0)
Surgical, Pharmacological, and Technological Advances: Highlights from the NYU Post-Graduate Medical School Course December 9-11, 1999, New York. (2000) (0)
Mp24-06 in Vivo Role of Nlrp3 Inflammasome in Innate Urothelial Defenses Against Uropathogenic E. Coli (2016) (0)
TEMPORALLY AND SPATIALLY CONTROLLED GENE EXPRESSION AND KNOCKOUT IN UROTHELIUM - NOVEL IN VIVO SYSTEMS FOR STUDYING UROTHELIAL FUNCTION AND DISEASES (2009) (0)
PD52-11 PSA SCREENING OF BLACK VETERANS BEFORE, DURING, AND AFTER IMPLEMENTATION OF THE 2012 US PREVENTATIVE SERVICES TASK FORCE RECOMMENDATIONS (2018) (0)
THE ABILITY OF VOLUME-ADJUSTED PSA PARAMETERS TO PREDICT PATHOLOGIC OUTCOME IN RADICAL PROSTATECTOMY (1999) (0)
NEW DIRECTIONS IN PROSTATE CANCER MANAGEMENT Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer (2007) (0)
Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone (2020) (0)
1965 INCONTINENCE ASSOCIATED WITH SEXUAL ACTIVITY: A PREVALENCE STUDY (2011) (0)
MP34-15 THE ROLE OF FERROPTOSIS IN NEUTROPHILS-MEDIATED INNATE IMMUNE DEFENSE AGAINST URINARY TRACT INFECTION (2023) (0)
A Prospective Pilot Study Investigating Performance of 18F-Fluciclovine PET Imaging for Detection of Prostate Cancer 2 Years Following Primary Partial Gland Cryoablation (2022) (0)
Geometry of hydrogel rectal spacer placement and risk of MRI-identified rectal wall infiltration. (2023) (0)
Effects of alpha-adrenergic agonist on neobladder water and electrolyte transport. (1994) (0)
PD38-07 ESSENTIAL ROLE OF HOST MICROBIOME IN COUNTERING EXPERIMENTAL HYPEROXALURIA, RENAL CALCINOSIS AND STONE FORMATION (2019) (0)
ROLE OF E-CADHERIN DEFICIENCY IN BLADDER TUMORIGENESIS AND PROGRESSION (2009) (0)
MP34-09 C-TERMINAL HYPER-PHOSPHORYLATION OF PTEN IS A MAJOR MECHANISM OF PTEN INACTIVATION IN BLADDER CANCER: IMPLICATIONS IN TUMOR SUPPRESSION AND MOLECULAR THERAPY (2014) (0)
MP51-13 HYPER-PHOSPHORYLATION OF PTEN IS A PRINCIPAL MECHANISM OF PTEN INACTIVATION IN HUMAN BLADDER CANCER (2019) (0)
MP73-10 PATIENT-REPORTED TREATMENT RELATED REGRET (TRR) FOLLOWING PRIMARY PARTIAL GLAND CRYOABLATION (PPGCA):A PROSPECTIVE COHORT STUDY OF MEN WITH LOCALIZED PROSTATE CANCER (2023) (0)
MP17-05 CORRELATION BETWEEN SINGLE-READER MRI-BASED PROSTATE VOLUME MEASUREMENTS AND SERUM PROSTATE-SPECIFIC ANTIGEN IN MEN WITH LOW-RISK PROSTATE CANCER ON ACTIVE SURVEILLANCE (2018) (0)
In Memoriam—Pablo A. Morales (1918-2016) (2017) (0)
Editorial comment. (2013) (0)
Focal Therapy of Prostate Cancer by Radiofrequency and Photodynamic Therapy (2013) (0)
Predictors of prostate cancer in the transition zone: Results of a multicenter trial (2007) (0)
PD38-11 WHOLE TRANSCRIPTOME ANALYSIS REVEALS MAJOR MOLECULAR PATHWAYS THAT POTENTIALLY DRIVE THE PROGRESSION OF CARCINOMA-IN-SITU TO MUSCLE-INVASIVE BLADDER CANCER (2016) (0)
UROTHELIUM-SPECIFIC INACTIVATION OF BOTH p53 AND Rb PROMOTES, BUT NOT INITIATES, INVASIVE BLADDER CARCINOMAS (2008) (0)
PD08-12 OUTCOMES AND TOXICITY AFTER PROSTATE SBRT IN MEN WITH VERY LARGE PROSTATE GLANDS (>100 cc) (2021) (0)
Axumin (18F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest (2022) (0)
MP39-12 P63 REGULATES DNA REPAIR AND MUTATOR PHENOTYPE OF BLADDER CANCER CELLS (2014) (0)
MP45-19 UPREGULATION OF ISOENZYME M2 OF PYRUVATE KINASE IN BLADDER CANCER: IMPLICATION IN TUMOR INITIATION, PROGRESSION AND THERAPEUTIC TARGETING. (2015) (0)
PSA Progression Postprostatectomy. (2000) (0)
66 IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP (RTOG) PROSTATE CANCER (PC) CLINICAL TRIALS (2009) (0)
MP16-02 ROLE OF SIMULTANEOUS TRUS GUIDED RANDOM BIOPSY IN MEN WITH UNILATERAL CANCER SUSPICIOUS REGIONS UNDERGOING MRI-US FUSION TARGETED PROSTATE BIOPSY (2016) (0)
MP33-02 TRANSCRIPTOME OF TAMM-HORSFALL PROTEIN-DEFICIENT KIDNEYS REVEALS SECONDARY EVENTS THAT MAY CONTRIBUTE TO INTRA-RENAL CALCINOSIS (2015) (0)
Editorial comment (0)
Reply from Author re: Thorsten Schlomm, Meike Adam. Quality of Life After Radical Prostatectomy: Can We Give a “Lifetime Guarantee” to Our Patients? Eur Urol 2014;65:66–7: Long-term Quality of Life Outcomes Following Radical Prostatectomy: Encouraging Observations (2014) (0)
Management Options for Nocturia. (2018) (0)
Salvage stereotactic body radiation therapy following definitive cryotherapy (2021) (0)
α-Adrenergic Blockade in the Treatment of Benign Prostatic Hyperplasia (1993) (0)
SIDE SPECIFIC FACTORS ASSOCIATED WITH EXTRACAPSULAR EXTENSION (ECE) AND SEMINAL VESICAL INVASION (SVI) IN MEN UNDERGOING OPEN RADICAL RETROPUBIC PROSTATECTOMY (ORRP) (2008) (0)
MP21-11 CLARITY ILLUMINATES THE STRUCTURAL AND MOLECULAR CHARACTERISTICS OF MOUSE GENITOURINARY TISSUES -- OVER AND OVER AGAIN (2015) (0)
PD38-03 USE OF PROSTATE SPECIFIC ANTIGEN SCREENING FOR VETERANS BEFORE, DURING, AND AFTER THE 2012 UNITED STATES PREVENTATIVE SERVICES TASK FORCE RECOMMENDATIONS: AGE AND RACE RELATED DIFFERENCES (2020) (0)
How Active is Active Surveillance ? Intensity of Follow-Up During Active Surveillance for Prostate Cancer in the United States Running Title : Intensity of Prostate Cancer Active Surveillance (2016) (0)
MP29-03 CDKN2A PLAYS A CRITICAL ROLE IN INNATE UROTHELIAL DEFENSES AGAINST UROPATHOGENIC E. COLI (2021) (0)
MP36-16 THE ROLE OF P63 AND P53MUTANT IN THE REGULATION OF DNA REPAIR, MUTATOR AND INVASIVE PHENOTYPE OF BLADDER CANCER CELLS (2015) (0)
Suprasacral Spinal Cord Injury Patients Managed by Reflex Voiding : Characterization of our Cohort (2009) (0)
MP5-17 RELATIONSHIP BETWEEN PATIENT EXPECTATIONS, FUNCTIONAL OUTCOMES, AND PATIENT SATISFACTION FOLLOWING RADICAL PROSTATECTOMY (2015) (0)
1052: Outcomes for Men Less than 50 Years of Age Undergoing Radical Prostatectomy: A Ratioinale for Earlier PSA Screening (2004) (0)
339 GLEASON 6 PROSTATE CANCERS DIAGNOSED IN THE PSA ERA ARE NEVER METASTATIC AT THE TIME OF RADICAL PROSTATECTOMY (2013) (0)
STROMAL AR INHIBITION OF PROSTATE CANCER GROWTH AND INVASION BY STROMAL AR AND ASSOCIATION WITH ANDROGEN INDEPENDENT DISEASE (2008) (0)
Commentary on Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of (2009) (0)
New Perspectives on Benign Prostatic Hyperplasia (2003) (0)
Iconographies supplémentaires de l'article : Long-term Satisfaction After Open Radical Prostatectomy (2015) (0)
Stereotactic Body Radiation Therapy for Ultra-Large (> 100 cc) Prostate Glands: Oncologic, Toxicity and Patient-Reported Outcomes. (2021) (0)
DO CANDIDATES FOR FOCAL THERAPY EXIST AMONG A CONTEMPORARY COHORT OF RADICAL PROSTATECTOMY PATIENTS (2008) (0)
MP20-03 NLRP3 INFLAMMASOME PLAYS A KEY ROLE IN UROTHELIAL DEFENSE AGAINST UROPATHOGENIC E. COLI (2015) (0)
S7 Prostatic Stem Cells : Location and Biological Properties (2006) (0)
MP02-18 THE RELATIVE CONTRIBUTION OF MRI FUSION TARGETED BIOPSY AND SYSTEMATIC BIOPSY VARY WITH INCREASING SERUM PSA LEVEL (2016) (0)
MP45-03 TAILLESS PTEN: A POTENT TUMOR SUPPRESSOR IN UROTHELIAL CARCINOMA CELLS (2016) (0)
Readership survey: reviews in urology. (2001) (0)
Therapy for Genitourinary Cancer (2012) (0)
Book Review Complications of Urologic Surgery: Prevention and management Second edition. Edited by Robert B. Smith and Richard M. Ehrlich. 669 pp., illustrated. Philadelphia, W.B. Saunders, 1990. $85. (1991) (0)
EDITORIAL COMMENT. (2019) (0)
PD32-05 GRADE CONCORDANCE OF TARGETED MRI-ULTRASOUND FUSION TARGETED PROSTATE BIOPSY RESULTS WITH FINAL PATHOLOGY FOLLOWING RADICAL PROSTATECTOMY (2015) (0)
EXPRESSION OF THE BTG2 ANTIPROLIFERATIVE GENE IN PROSTATE CANCER (1999) (0)
Platinum Priority – Prostate Cancer Editorial by Thorsten Schlomm and Meike Adam on pp . 66 – 67 of this issue Ten-year Outcomes of Sexual Function After Radical Prostatectomy : Results of a Prospective Longitudinal Study (2013) (0)
MP36-08 APPLICATION OF THE PRECISION TRIAL BIOPSY STRATEGY TO A CONTEMPORARY COHORT: HOW MANY CLINICALLY SIGNIFICANT PROSTATE CANCERS ARE MISSED? (2019) (0)
MP70-18 MPMRI PREDICTS URETHRAL INVOLVEMENT IN MEN UNDERGOING RADICAL PROSTATECTOMY: IMPLICATIONS FOR CRYOABLATION (2020) (0)
イヌ・ヒト前立腺に対すEndothelin-1(ET-1)の生理学的、薬理学的研究 (1997) (0)
MP20-16 COVID-19 IMPACT ON UROLOGY RESIDENT ROTATION CASE VOLUME (2021) (0)
OUTCOMES OF REPEAT MRI‐US FUSION‐TARGETED BIOPSY IN MEN WITH INITIALLY LOW RISK OR NEGATIVE FUSION BIOPSY: PD61‐05 (2017) (0)
Abstract 3563: Soy protein isolate consumption does not prevent biochemical failure after radical prostatectomy in high risk men: A randomized controlled trial (2012) (0)
MP83-11 GAIN-OF-FUNCTION OF P53 POINT MUTATIONS IN BLADDER CANCER DEVELOPMENT (2016) (0)
143: A 24 Month Longitudinal Study of Orgasmic Quality in 228 Men After Radical Retropubic Prostatectomy (2004) (0)
AUTHOR REPLY. (2021) (0)
Molecular Markers for Prostate Cancer Risk Stratification from Multiple Ultrasound-Guided Biopsies (2014) (0)
MP03-05 HYPERPHOSPHATURIA OR HYPEROXALURIA EXACERBATES INTRA-RENAL CALCIFICATION BUT NOT STONE FORMATION IN TAMM-HORSFALL PROTEIN KNOCKOUT MICE (2019) (0)
PATHOPHYSIOLOGY AND PREVALENCE, ALPHA BLOCKADE AND COMBINATION THERAPY OF BENIGN PROSTATIC HYPERPLASIA (1997) (0)
Surgical, Pharmacological, and Technological Advances in Adult and Pediatric Urology-State of the Art: Highlights of the 8th Annual NYU Department of Urology Post-Graduate Course December 6-8, 2001, New York, NY. (2003) (0)
344 PREOPERATIVE STATIN THERAPY (ST) IS NOT ASSOCIATED WITH PROLONGED BIOCHEMICAL FREE SURVIVAL (BCFS) AFTER RADICAL PROSTATECTOMY (RP) A META-ANALYSIS OF FIVE RETROSPECTIVE STUDIES (2012) (0)
NOTCH SIGNALING IS REQUIRED FOR EPITHELIAL DIFFERENTIATION IN THE PROSTATE GLAND (2009) (0)
Decision tree algorithms for prostate cancer detection Complexed PSA and other significant predictors using CHAID analysis (2002) (0)
MP73-14 BIOPSY ASSESSMENT OF ONCOLOGIC CONTROL THREE YEARS FOLLOWING PRIMARY PARTIAL GLAND CRYOABLATION (PPGCA) (2023) (0)
Editorial comment. (2010) (0)
394: The Proximal Region of Murine Prostatic Ducts is Enriched in Prostate Stem Cells (2004) (0)
PD57-03 PREDICTORS OF CONTRALATERAL DISEASE IN MEN WITH UNILATERAL LESIONS ON MULTIPARAMETRIC MRI (2022) (0)
860: Protein C Inhibitor as a Biomarker for Prostate Cancer: Detection, Staging, and Prediction of Recurrence (2006) (0)
1570 DIFFERENTIATION OF THE DUCTAL EPITHELIUM AND SMOOTH MUSCLE IN THE PROSTATE GLAND ARE REGULATED BY THE NOTCH/PTEN-DEPENDENT MECHANISM (2011) (0)
MP36-20 DEFINING THE MOLECULAR DRIVERS OF HIGH-GRADE NON-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER (2015) (0)
Editorial comment. (2012) (0)
PD42-04 THE DYSBIOSIS OF MICROBIOTA AFFECTS BLADDER INFLAMMATION AND CARCINOGENESIS OF MUSCLE INVASIVE BLADDER CANCER (2020) (0)
785 COMPENSATORY TUMOR DEFENSES IN UROTHELIUM DURING TUMOR SUPPRESSOR DEFICIENCY: IMPLICATION ON THE REQUIREMENT OF MULTI-GENE DEFECTS IN INVASIVE CARCINOMA FORMATION (2010) (0)
前立腺におけるNitric Oxide Synthase Nerve (1995) (0)
Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group (RTOG) prostate clinical trials. (2009) (0)
Advances in the medical treatment of benign prostatic hyperplasia. (2009) (0)
PREOPERATIVE DIAGNOSIS OF INGUINAL HERNIAS (IHS) IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY (RRP) (2009) (0)
DOES NERVE SPARING (NS) OR POTENCY STATUS IMPACT CONTINENCE FOLLOWING OPEN RADICAL RETROPUBIC PROSTATECTOMY (ORRP) (2008) (0)
Urology. Controversies old and new. (1995) (0)
MP56-19 10-YEAR MORTALITY AFTER RADICAL PROSTATECTOMY IN THE PROSTATE-SPECIFIC ANTIGEN SCREENING ERA (2015) (0)
Prostate magnetic resonance imaging‐targeted biopsy global grade correlates better than highest grade with prostatectomy grade (2022) (0)
Editorial Comment: Doxazosin in the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients (1995) (0)
Prostate specific antigen density of the transition zone for early detection of prostate cancer: Editorial comment (1998) (0)
MP45-05 UROTHELIUM-SPECIFIC AND TEMPORALLY CONTROLLED BI-ALLELIC INACTIVATION OF BOTH PTEN AND P53 TRIGGERS BASAL-SUBTYPE MUSCLE-INVASIVE BLADDER CANCER (2016) (0)
PD37-11 STATIN THERAPY MAY IMPROVE LONG-TERM SEXUAL FUNCTION AFTER RADICAL PROSTATECTOMY (2015) (0)
Adult Urology Inguinal Hernias in Men Undergoing Open Radical Retropubic Prostatectomy (2007) (0)
MP56-01 SIZE-ADJUSTED QUANTITATIVE GLEASON SCORE AS A PREDICTOR OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2015) (0)
MP09-05 HEAD TO HEAD COMPARISON OF 4KSCORE® AND SELECTMDX® TO GUIDE PROSTATE BIOPSY DECISION MAKING (2020) (0)
812 Defects in the endoderm survival and polarity of cell divisions in the mouse model for rectourethral malformations (2012) (0)
THE PRODUCT OF THE BTG2 ANTIPROLIFERATIVE GENE IS ABUNDANTLY EXPRESSED IN GLANDULAR ATROPHY (1999) (0)
Assessing quality of life following radiotherapy. (2002) (0)
Adjuvant hormonal therapy in men with node-positive prostate cancer. (2000) (0)
COMPARISON OF PATHOLOGIC AND ONCOLOGIC OUTCOMES OF RADICAL RETRO PUBIC PROSTATECTOMY AMONG MEN WITH UNILATERAL VS. BILATERAL PROSTATE CANCER: IMPLICATIONS FOR FOCAL THERAPY (2008) (0)
THE IMPORTANCE OF VOLUME-SPECIFIC SENSITIVITY CUT-OFFS IN THE APPLICATION OF VOLUME-ADJUSTED PSA PARAMETERS (1999) (0)
PD32-03 OUTCOMES OF MRI-US FUSION TARGETED PROSTATE BIOPSY IN MEN WITH HISTORY OF PREVIOUS NEGATIVE BIOPSY: IMPROVED CANCER DETECTION AND RISK STRATIFICATION. (2015) (0)
BMP7 directs epithelial cell fate choice and dorsal–ventral partitioning of the embryonic cloaca by collaborating with the PCP pathway (2011) (0)
V14-05 MRI FUSION GUIDED PROSTATE PARTIAL GLAND CRYOABLATION AIDED BY A VIRTUAL 3D MODELING: A STEP BY STEP ILLUSTRATION (2020) (0)
1466: Longterm Follow-Up of Hgpin: The Natural History of Progression to Prostate Cancer (2005) (0)
of its kidney-specific activity in transgenic mice Isolation of mouse THP gene promoter and demonstration (2016) (0)
Opening up New Therapeutic Avenues (2016) (0)
DOWN‐REGULATION OF PYRUVATE KINASE 2 BY RNAI AND SMALL MOLECULE INHIBITOR OVERCOMES CISPLATIN RESISTANCE OF BLADDER CANCER CELLS IN VITRO AND IN VIVO: MP98‐16 (2017) (0)
Management of intraoperative complications associated with open radical prostatectomy (2007) (0)
Prostatic Diseases and Male Voiding Dysfunction Does Open Radical Retropubic Prostatectomy Decrease the Risk of Acute Urinary Retention (2008) (0)
144 UNILATERAL POSITIVE PROSTATE BIOPSY PREDICTS MORE FAVORABLE PATHOLOGIC AND ONCOLOGIC OUTCOMES IN SELECTION OF CANDIDATES FOR FOCAL THERAPY (2010) (0)
Editorial comment. (2014) (0)
Immunosuppressive milieu of high-risk localized prostate cancer. (2020) (0)
PD32-01 COMPARISON OF MRI-US FUSION TARGETED BIOPSY AND SYSTEMATIC PROSTATE BIOPSY: SINGLE INSTITUTION EXPERIENCE IN 604 PATIENTS. (2015) (0)
2218 A PROSPECTIVE COMPARATIVE STUDY OF TARGETED PROSTATE BIOPSY DIRECTED TO MRI-SUSPICIOUS REGIONS VERSUS ARTEMIS™ COMPUTERIZED 12 CORE TEMPLATE BIOPSY (2013) (0)
MP53-19 INTERACTION OF PSA AND MRI SUSPICION SCORE ON THE CANCER DETECTION RATE OF MRI FUSION TARGETED BIOPSY (2016) (0)
ACTIVE SURVEILLANCE OF MEN WITH HGPIN BY EMPIRIC DELAYED INTERVAL BIOPSIES DEMONSTRATES A SIGNIFICANT LONG-TERM RISK OF CANCER PROGRESSION (2008) (0)
MP25-02 DIVERGENT RESPONSES OF MICE LACKING TAMM-HORSFALL PROTEIN, OSTEOPONTIN OR BOTH TO HYDROXYPROLINE-INDUCED HYPEROXALURIA (2014) (0)
Author response: The role of TAp63γ and P53 point mutations in regulating DNA repair, mutational susceptibility and invasion of bladder cancer cells (2021) (0)
Editorial Comment. (2016) (0)
CONVENTIONAL PROSTATE BIOPSY PREDICTS THE LATERALITY OF DOMINANT DISEASE AMONG FOCAL THERAPY CANDIDATES WITH BILATERAL PROSTATE CANCER (2009) (0)
PD47-09 OPTIMIZING USE OF MRI-US FUSION TARGETED BIOPSY: UPDATED EXPERIENCE IN 1639 COMBINED SYSTEMATIC AND TARGETED PROSTATE BIOPSIES (2018) (0)
The Use of Pharmacologic Agents for Benign Prostatic Hyperplasia (1994) (0)
Prostatic intraepithelial neoplasia in a 53-year-old man. (2005) (0)
POS-01.83: Six-month interim analysis return of erectile function from a randomized study of nightly intraurethral alprostadil vs sildenafil as penile rehabilitation in post bilateral nerve sparing radical prostatectomy (BNSRRP) (2007) (0)
LEUKOTRIENE B4 SIGNALING ACTIVATES INNATE UROTHELIAL DEFENSES AND PROTECTS THE BLADDER AND KIDNEYS AGAINST UROPATHOGENIC E. COLI (UPEC): PD12‐04 (2017) (0)
Salvage Prostate Stereotactic Body Radiation Therapy After Definitive Cryoablation (2021) (0)
MP36-19 RAS ACTIVATION SYNERGIZES WITH P53 DEFICIENCY TO PROVOKE EPITHELIAL-MESENCHYMAL TRANSITION FORMING CANCER PROGENITOR CELLS AND TRIGGERING BASAL SUBTYPE MUSCLE INVASIVE BLADDER CANCER (2015) (0)
DOES RESIDUAL BENIGN PROSTATE TISSUE CONTRIBUTE TO DETECTABLE PSA LEVELS FOLLOWING RADICAL RETROPUBIC PROSTATECTOMY (RRP) (2008) (0)
MP44-07 THE USE OF CLARITY-OPTIMIZED LIGHT-SHEET MICROSCOPY (COLM) FOR HIGH RESOLUTION IMAGING OF THE ADULT MOUSE PROSTATE (2016) (0)
MP53-15 BIOPSY RESULTS AMONG MEN UNDERGOING REPEAT MRI-ULTRASOUND FUSION TARGETED BIOPSIES (2015) (0)
MP77-17 PERFORMANCE OF URINARY BIOMARKER PCA3 AMONG MEN UNDERGOING TARGETED MRI-ULTRASOUND FUSION BIOPSY (2015) (0)
PD43-11 CHARACTERISTICS AND MANAGEMENT OF MEN DEVELOPING LATE BIOCHEMICAL RECURRENCE (LBCR) FOLLOWING RADICAL PROSTATECTOMY (RP) (2015) (0)
MP46-05 MITOCHONDRIA OF UROTHELIAL UMBRELLA CELLS PLAY A CENTRAL ROLE IN DETOXIFICATION TO REMOVE DYSFUNCTIONAL PROTEINS AND CERTAIN URINARY TOXINS: IMPLICATIONS IN MAJOR BLADDER DISEASES (2020) (0)
1127 QUANTIFICATION OF MAJOR BLADDER CARCINOGENS - ACROLEIN AND AMINOBIPHENYL-INDUCED DNA ADDUCTS IN NORMAL HUMAN UROTHELIAL MUCOSA AND BLADDER TUMOR TISSUE (2013) (0)
Letter from the editors of reviews in urology. (2001) (0)
IL-9 Incidence prevention and management of urinary incontinence following radical prostatectomy (RP) (2004) (0)
SONOCYSTOGRAPHY FOLLOWING OPEN RADICAL RETROPUBIC PROSTATECTOMY (ORRP) (2008) (0)
TRANSPERINEAL ULTRASONOGRAPHY : POTENTIAL FOR A NEW STANDARD IN ASSESSING ANASTOMOTIC LEAK POST-RADICAL PROSTATECTOMY (2009) (0)
Management of High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) (2013) (0)
Landmark studies impacting the medical management of benign prostatic hyperplasia. (2003) (0)
MP55-10 A PROSPECTIVE LONGITUDINAL STUDY OF ERECTILE FUNCTION FOLLOWING PARTIAL GLAND CRYOABLATION FOR INTERMEDIATE RISK PROSTATE CANCER (2022) (0)
In Reply: Re (1996) (0)
The role of TAp63γ and P53 point mutations in regulating DNA repair, mutational susceptibility and invasion of bladder cancer cells (2021) (0)
1269: Ultrasensitive Serum PSA Nadir Accurately Predicts the Risk of Early Relapse after Radical Prostatectomy (2004) (0)
The Challenge for Urologists Is to Screen, Detect, and Treat Prostate Cancer "Smarter": Will Ablative Technology Result in Smarter Treatment? (2016) (0)
PD04-02 EXPERIMENTAL EVIDENCE OF HEIGHTENED RISKS OF RENAL CALCINOSIS AND STONE FORMATION IN MICE TREATED WITH ANTIBIOTICS AND UNDER HYPEROXALURIA (2020) (0)
439 URINARY FUNCTION IS STABLE BETWEEN 2 AND 10 YEARS FOLLOWING RADICAL PROSTATECTOMY (RP) (2013) (0)
Editorial Comment. (2016) (0)
PREDICTING ONCOLOGICAL CONTROL FOLLOWING FOCAL ABLATION(FA) OF PROSTATE CANCER(PCA): MP70‐06 (2017) (0)
Long-term Follow-up of a Prospective Phase I-II Study of Concurrent Paclitaxel and Radiation Therapy With Hormonal Ablation in Locally Advanced Prostate Cancer (2012) (0)
2 Year Functional Outcomes Stratified According to Baseline Erectile Function Following Partial Gland Cryo-Ablation. (2022) (0)
V02-09 RADICAL PROSTATECTOMY FOR LOCALLY ADVANCED PROSTATE CYSTADENOCARCINOMA USING THE DA VINCI SP® SYSTEM (2020) (0)
MP34-10 CROSSTALK BETWEEN DOWNSTREAM EFFECTORS OF RECEPTOR TYROSINE KINASE/RAS PATHWAY CAN BE DISRUPTED BY COMBINATORIAL INHIBITION: IMPLICATION IN TARGETED THERAPY (2014) (0)
ESTABLISHMENT OF A NORMAL NOVEL MOUSE SMOOTH MUSCLE PROSTATE CELL LINE (1999) (0)
OUTCOMES OF MRI‐US FUSION‐TARGETED BIOPSY IN MEN WITH NO PREVIOUS BIOPSY: OPPORTUNITY TO REDUCE BIOPSY UTILIZATION AND SECONDARY OVER‐DETECTION: MP38‐13 (2017) (0)
MP24-07 MULTINUCLEATED UROTHELIAL UMBRELLA CELLS AS INITIATORS OF INNATE HOST DEFENSES AGAINST UROPATHOGENIC E. COLI (2016) (0)
American Uro-Gynecologic Society and the Uro-Dynamics Society 1993 Annual Scientific Meeting (2004) (0)
ヒトの前立腺α1-アドレナリン受容体およびリコンビナントα1-サブタイプにおけるドキサゾシン光学異性体の薬理学的特異性 (1996) (0)
A prospective study of cancer detection rates following early repeat imaging and biopsy of PI-RADS 4 and 5 regions of interest exhibiting no clinically significant prostate cancer on prior biopsy. (2022) (0)
EPITHELIAL AND STROMAL MICRORNA EXPRESSION IN RACIAL DISPARITY OF PROSTATE CANCER (2009) (0)
Long-term Natural History of Lower Urinary Tract Symptoms Following Radical Retropubic Prostatectomy: A Prospective 15-Year Longitudinal Study. (2018) (0)
Surgical, Pharmacological, and Technological Advances in Adult and Pediatric Urology: Highlights from the NYU Post-Graduate Medical School course December 10-12, 1998 New York, NY. (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Herbert Lepor?

Herbert Lepor is affiliated with the following schools:

Herbert Lepor's Academic­Influence.com Rankings

Herbert Lepor's Degrees

Why Is Herbert Lepor Influential?

Herbert Lepor's Published Works

Published Works

What Schools Are Affiliated With Herbert Lepor?

Herbert Lepor's AcademicInfluence.com Rankings